Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?

Lipoprotein (a) [Lp(a)] has been recognized as an independent, inherited, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, thus representing a major target of residual CV risk. Currently, no drug has been officially approved for lowering Lp(a) levels,...

Full description

Bibliographic Details

Published in:	Pharmaceuticals
Main Authors:	Niki Katsiki, Michal Vrablik, Maciej Banach, Ioanna Gouni-Berthold
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Subjects:	lipoprotein (a) pelacarsen olpasiran zerlasiran lepodisiran muvalaplin
Online Access:	https://www.mdpi.com/1424-8247/18/5/753